[Gettyimages Bank]
The joint research has been conducted by the National Institute of Health (NIH), a state body controlled by the Korea Centers for Disease Control and Prevention (KCDC), and Gyeonggido Business and Science Accelerator (GBSA), which carries out a variety of projects for small and medium companies in Gyeonggi Province.
Originally, Gyeonggi Province has pushed for a project to develop a treatment for MERS by using raloxifene, which is sold under the brand name Evista and used to prevent and treat osteoporosis in postmenopausal women and those on glucocorticoids. The drug is also used to reduce the risk of breast cancer.
In a joint study, NIH and GBSA proved that raloxifene has the effect of inhibiting the novel coronavirus' activity at the cell level. Raloxifene has a clear safety as a drug already on the market. GBSA and three hospitals have formed a consultative body to secure approval from the Ministry of Food and Drug Safety for clinical trials.
Copyright ⓒ Aju Press All rights reserved.
Related News
-
Biohealth Industry Future Discussed at Gwangju Biohealth Week in Yeosu
A forum to explore the future growth drivers of the biohealth industry in Gwangju, Jeonnam, will take place in Yeosu. The Jeonnam Bio Promotion Agency announced that it will host the '2nd Gwangju Biohealth Week 2026' on November 19 at the JCS Hotel in Yeosu, under the theme 'Unified Gwangju, A Greater Future for Biohealth.' The event is expected to attract over 250 participants from bio companies, universities, research institutions, and hospitals, who will share insights on policy directions and the latest technological trends in the biohealth sector while discussing growth strategies for the local industry. Following last year's 'Southwest Biohealth Week 2025,' this second event aims to consolidate the research, development, manufacturing, and commercialization capabilities of the Gwangju region, focusing on linking corporate support and investment attraction. The program will begin at 10:30 a.m. with participant registration, followed by a welcome ceremony, declaration ceremony, expert lectures, a corporate support program briefing, and an exhibition of achievements. In particular, the afternoon expert lectures will focus on strategies for creating advanced medical complexes, new drug development, regenerative medicine, and attracting corporate investments, which are crucial for the future competitiveness of the local biohealth industry. Lee Seong-kyu, head of the K-Health Future Promotion Team, will introduce the Korean-style ARPA-H project, while Sun Kyung, director of the project, will discuss the necessity of establishing an advanced medical complex in the Honam region and strategies for linking it with the Korean-style ARPA-H project. Following that, Oh Il-woong, head of the Vaccine Safety Technology Support Center, will explain the application of new approach methodologies (NAMs) in the biohealth sector and regulatory trends. Park Jeong-tae, vice president of the Korea Bio Pharmaceutical Association, will present opportunities, challenges, and response strategies for K-Bio's entry into the global market. Discussions on attracting investments necessary for the growth of bio companies and future medical technologies will also take place. Kim Seong-ha, head of Gravity Ventures' investment division, will introduce venture investment procedures and strategies for attracting investments at various stages of startup growth. Yoon Taek-rim, director of the Regenerative Medicine Promotion Foundation, will give a lecture on the potential for development in regenerative medicine and treatments for aging and incurable diseases. The corporate support program briefing will cover initiatives such as support for green bio companies, scale-up support for bio firms, startup investment support, and fostering K-pharmaceutical and bio frontier companies. Through this, local bio companies are expected to identify suitable support programs for their growth stages and seek collaborative opportunities that link technology development, commercialization, and investment attraction. The event will also feature a sharing of achievements from the K-Biohealth Regional Center support program and an exhibition of key outcomes from supported companies. The Jeonnam Bio Promotion Agency will also introduce major research and development projects and industrial foundation-building initiatives, including AI-based vaccine manufacturing and quality control, standardization of natural material resources, and domestic production of raw materials based on agricultural and biological resources. Park Seong-yoon, head of the Strategic Planning Office at the Jeonnam Bio Promotion Agency, stated, "This event will gather the biohealth capabilities of Gwangju and share policy, technology, and investment information needed by companies. We aim to expand opportunities for technology commercialization and growth for local companies based on collaboration among industry, academia, research, and hospitals, thereby enhancing the competitiveness of the bio industry." Meanwhile, the Jeonnam Bio Promotion Agency plans to expand its collaborative foundation to ensure that the research and development achievements of the local biohealth industry lead to tangible growth for companies and strengthen industrial competitiveness. As the establishment of an advanced medical complex in the Honam region and the potential for linking with national research and development projects are key agenda items, attention is focused on whether specific collaborative projects and follow-up achievements will emerge in the future.* This article has been translated by AI.
-
Six Policy Finance Institutions Visit Daegu to Address Local Business Funding Issues
The Financial Services Commission met with six policy finance institutions to listen to the challenges faced by businesses in the Daegu and Gyeongbuk regions and discuss support measures.On November 13, the Financial Services Commission held the second 'Policy Finance Collaboration' event at EXCO in Daegu, featuring six policy finance institutions: the Korea Development Bank, Industrial Bank of Korea, Korea Credit Guarantee Fund, Korea Trade Insurance Corporation, Export-Import Bank of Korea, and Korea Technology Finance Corporation.The Policy Finance Collaboration is a platform for policy finance institutions to engage directly with local industries, addressing financial challenges faced by businesses and discussing financial support measures. This event follows the first collaboration held in Daejeon in June.More than 80 companies from the Daegu and Gyeongbuk regions participated in this event. The policy finance institutions listened to the financial difficulties of local businesses and introduced key support programs, including the National Growth Fund and local preferential financing.According to the announcement, as of October this year, four policy finance institutions—Korea Development Bank, Industrial Bank of Korea, Korea Credit Guarantee Fund, and Korea Technology Finance Corporation—have provided a total of 95.8 trillion won in policy finance to non-capital region areas. This amount represents 44.5% of the total supply, exceeding the annual target of 41.7%.The government plans to gradually increase the share of policy finance supplied to local areas from 40% last year to 45% by 2028.Support from the National Growth Fund for fostering local advanced industries will also be expanded. Starting next year, the fund's operational scale is set to increase to 40 trillion won annually, totaling over 200 trillion won over five years.As of October this year, the National Growth Fund's support amounted to 22.7 trillion won, with 9 trillion won allocated to non-capital regions.Specific support cases for local businesses were also disclosed. The Korea Development Bank provided 300 billion won in loans for vaccine research and development and production facility expansion projects in Gyeongbuk, and 220 billion won for establishing a lithium iron phosphate (LFP) cathode material production facility in Daegu. The Industrial Bank of Korea lent 32.7 billion won to a manufacturer of advanced machinery in Daegu, while the Korea Credit Guarantee Fund provided 2.8 billion won in guarantees to a non-ferrous metal rolling manufacturer.Moving forward, the Financial Services Commission and the six policy finance institutions plan to hold 'Policy Finance Collaboration' events sequentially in major cities across regions to enhance communication with local businesses.In his opening remarks, An Chang-guk, a standing commissioner of the Financial Services Commission, emphasized, "The Daegu-Gyeongbuk region is a hub for future industries, concentrating capabilities in advanced sectors such as semiconductors, mobility, and robotics. It is not an exaggeration to say that the competitiveness of our advanced industries depends on the development of the Daegu-Gyeongbuk region's industries."* This article has been translated by AI.
-
Aribio Lab Unveils Alzheimer's Vaccine Development Plans
Aribio Lab, formerly known as Cha Vaccine Research Institute, is set to unveil its plans for developing an Alzheimer's disease prevention vaccine ahead of a change in its major shareholder.The company announced on November 10 that it will participate in the Korean Immunology Society International Conference (KAI 2026) from November 12 to 14 at Songdo Convensia in Incheon, where it will present its new pipeline for vaccines targeting degenerative brain diseases, including Alzheimer's, as well as developments in the anti-aging sector.Aribio Lab will introduce its proprietary immune adjuvant platform technology and the current status of its key vaccine pipelines, along with plans for future projects in neuroimmunology and immune aging. A company representative stated, "We will reveal our vision to expand our business structure, which has focused on infectious disease vaccines, to include neuroimmunology and immune aging control."The most advanced clinical pipeline is the recombinant shingles vaccine 'CVI-VZV-001.' It has completed the second administration in a Phase 2 clinical trial involving 135 adults aged 50 and older, with topline results expected in the first quarter of next year before entering Phase 3 trials.The company is also broadening the scope of its platform applications. Aribio Lab is developing an mRNA-based immune cancer treatment as part of a national new drug development project. Additionally, it is working on South Korea's first recombinant Japanese encephalitis vaccine under a project funded by the Ministry of Health and Welfare.The company emphasizes that its proprietary immune adjuvant platforms, 'L-pampo' and 'Lipo-pam,' are key competitive advantages. These technologies stimulate innate immune receptors TLR1/2 and TLR3 simultaneously, inducing both humoral and cellular immunity. They can be expanded for use in preventive vaccines, therapeutic vaccines, and immunotherapy.Lipo-pam is the only technology from a domestic company listed in the UK Medicines and Healthcare products Regulatory Agency (MHRA) and the Coalition for Epidemic Preparedness Innovations (CEPI) 'Vaccine Adjuvant Library.' The company plans to pursue collaborative research and technology transfers with global vaccine developers based on this recognition.Previously, Aribio completed a global Phase 3 clinical trial for its oral Alzheimer's treatment 'AR1001.' Detailed clinical results will be presented at the Alzheimer's Clinical Trials Conference (CTAD 2026) in Boston on November 16.Building on this foundation, Aribio Lab aims to research preventive approaches to degenerative brain diseases and neuroimmunology modulation technologies, leveraging its experience in immune adjuvant platforms and vaccine development.The company continues to advance its existing vaccine pipeline. The shingles vaccine 'CVI-VZV-001' has confirmed safety and a 100% seroprotection rate in Phase 1 trials and has completed administration in Phase 2 trials. The company plans to announce Phase 2 results in the first quarter of 2027 and pursue subsequent clinical development.Jae-jun Jeong, CEO of Aribio Lab, stated, "The drug development capabilities of Aribio and the immune adjuvant platform of Aribio Lab are mutually complementary strengths, and we believe this will create new business opportunities that encompass both treatment and prevention."* This article has been translated by AI.